Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Date Issued
2024-01-08
Author(s)
Luo, Yung-Hung
Chang, Gee-Chen
Chang, John Wen-Cheng
Wang, Chin-Chou
Yang, Tsung-Ying
Fang, Wei-Tse
Shau, Wen-Yi
Abstract
Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression despite prior treatment with ALK tyrosine kinase inhibitors (TKIs) was assessed. Herein, we report real-world clinical outcomes of lorlatinib-treated patients with ALK-positive advanced NSCLC who were heavily pretreated and progressed on first- and second-generation ALK-TKIs, in a Taiwanese population under the lorlatinib expanded access program (EAP).
Subjects
ALK; Lorlatinib; NSCLC
Type
journal article